ANI Pharmaceuticals, Inc. announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Powder. ANI?s L-Glutamine Oral Powder is the generic version of the reference listed drug (RLD) Endari®. U.S. annual sales for L-Glutamine Oral Powder total approximately $20.1 million, based on May 2024 moving annual total (MAT) IQVIA data.